KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to $58.7 billion.

  • Gsk's Non-Current Assets rose 1082.53% to $58.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $58.7 billion, marking a year-over-year increase of 1082.53%. This contributed to the annual value of $54.3 billion for FY2024, which is 812.98% up from last year.
  • Latest data reveals that Gsk reported Non-Current Assets of $58.7 billion as of Q3 2025, which was up 1082.53% from $55.5 billion recorded in Q2 2025.
  • Gsk's Non-Current Assets' 5-year high stood at $83.3 billion during Q3 2021, with a 5-year trough of $39.9 billion in Q1 2022.
  • Its 5-year average for Non-Current Assets is $57.1 billion, with a median of $52.4 billion in 2024.
  • Its Non-Current Assets has fluctuated over the past 5 years, first plummeted by 5143.05% in 2022, then soared by 1847.59% in 2023.
  • Over the past 5 years, Gsk's Non-Current Assets (Quarter) stood at $81.5 billion in 2021, then crashed by 43.3% to $46.2 billion in 2022, then rose by 8.46% to $50.1 billion in 2023, then increased by 8.81% to $54.5 billion in 2024, then rose by 7.66% to $58.7 billion in 2025.
  • Its Non-Current Assets was $58.7 billion in Q3 2025, compared to $55.5 billion in Q2 2025 and $53.7 billion in Q1 2025.